Previous 10 |
BOSTON , April 25, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced completion of...
Results from the open-label extension of the Phase 2/3 TAZPOWER study evaluating Stealth BioTherapeutics' (NASDAQ: MITO ) Orphan Drug- and Fast Track-tagged elamipretide in patients with genetically confirmed Barth syndrome showed a positive effect on cardiolipin levels. The data were p...
The first quarter of 2019 was robust with activity for the biotechnology industry thanks to merger and acquisitions (M&A) in addition to initial public offerings (IPOs). Looking back to the end of last year, the biotech sector took a significant hit in terms of stock performance, ...
BOSTON , April 16, 2019 /PRNewswire/ -- Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced positive results from t...
News, Short Squeeze, Breakout and More Instantly...
Stealth BioTherapeutics Corp. Company Name:
MITO Stock Symbol:
NYSE Market:
Stealth BioTherapeutics Corp Announces Completion of Merger PR Newswire BOSTON , Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the ...
Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective...
Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders PR Newswire BOSTON , Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused o...